Do analysts recommend MDLN or PHG?

Medline currently has a consensus target price of $50.54, indicating a potential upside of 48.82%. Given Medline's stronger consensus rating and higher probable upside, analysts plainly believe Medline is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medline 1 Sell rating(s) 5 Hold rating(s) 22 Buy rating(s) 1 Strong Buy rating(s) 2.79 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, MDLN or PHG?

Koninklijke Philips has lower revenue, but higher earnings than Medline. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medline $28.43B 1.57 N/A N/A N/A Koninklijke Philips $20.17B 1.24 $1.01B $1.17 22.12

Does the media refer more to MDLN or PHG?

In the previous week, Medline had 7 more articles in the media than Koninklijke Philips. MarketBeat recorded 10 mentions for Medline and 3 mentions for Koninklijke Philips. Medline's average media sentiment score of 0.46 beat Koninklijke Philips' score of 0.40 indicating that Medline is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medline 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PHG or GEHC?

GE HealthCare Technologies has a consensus target price of $80.21, indicating a potential upside of 24.26%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, analysts plainly believe GE HealthCare Technologies is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 GE HealthCare Technologies 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor PHG or GEHC?

In the previous week, GE HealthCare Technologies had 12 more articles in the media than Koninklijke Philips. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 3 mentions for Koninklijke Philips. GE HealthCare Technologies' average media sentiment score of 1.01 beat Koninklijke Philips' score of 0.40 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GE HealthCare Technologies 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PHG or ZBH?

Zimmer Biomet has a consensus price target of $102.70, indicating a potential upside of 18.24%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zimmer Biomet 3 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.26

Does the media prefer PHG or ZBH?

In the previous week, Zimmer Biomet had 15 more articles in the media than Koninklijke Philips. MarketBeat recorded 18 mentions for Zimmer Biomet and 3 mentions for Koninklijke Philips. Zimmer Biomet's average media sentiment score of 0.93 beat Koninklijke Philips' score of 0.40 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zimmer Biomet 12 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SOLV or PHG?

Solventum presently has a consensus target price of $84.25, suggesting a potential upside of 2.61%. Given Solventum's stronger consensus rating and higher probable upside, research analysts clearly believe Solventum is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solventum 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor SOLV or PHG?

In the previous week, Solventum and Solventum both had 3 articles in the media. Koninklijke Philips' average media sentiment score of 0.40 beat Solventum's score of 0.25 indicating that Koninklijke Philips is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SNN or PHG?

Smith & Nephew SNATS presently has a consensus price target of $30.93, suggesting a potential upside of 1.78%. Given Smith & Nephew SNATS's stronger consensus rating and higher probable upside, research analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew SNATS 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Koninklijke Philips 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, SNN or PHG?

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.10 $625M N/A N/A Koninklijke Philips $20.17B 1.24 $1.01B $1.17 22.12

Does the media prefer SNN or PHG?

In the previous week, Koninklijke Philips had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 3 mentions for Koninklijke Philips and 2 mentions for Smith & Nephew SNATS. Koninklijke Philips' average media sentiment score of 0.40 beat Smith & Nephew SNATS's score of 0.00 indicating that Koninklijke Philips is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew SNATS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Koninklijke Philips (PHG) Competitors

$25.88 +0.53 (+2.11%)

As of 11:11 AM Eastern

Compare

PHG vs. MDLN, GEHC, ZBH, SOLV, and SNN

Should you buy Koninklijke Philips stock or one of its competitors? MarketBeat compares Koninklijke Philips with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Koninklijke Philips include Medline (MDLN), GE HealthCare Technologies (GEHC), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Koninklijke Philips compare to Medline?

Medline (NASDAQ:MDLN) and Koninklijke Philips (NYSE:PHG) are both large-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

Koninklijke Philips has lower revenue, but higher earnings than Medline.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.57	N/A	N/A	N/A
Koninklijke Philips	$20.17B	1.24	$1.01B	$1.17	22.12

In the previous week, Medline had 7 more articles in the media than Koninklijke Philips. MarketBeat recorded 10 mentions for Medline and 3 mentions for Koninklijke Philips. Medline's average media sentiment score of 0.46 beat Koninklijke Philips' score of 0.40 indicating that Medline is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

13.7% of Koninklijke Philips shares are held by institutional investors. 0.8% of Medline shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Koninklijke Philips has a net margin of 5.49% compared to Medline's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Koninklijke Philips	5.49%	13.51%	5.48%

Medline currently has a consensus target price of $50.54, indicating a potential upside of 48.82%. Given Medline's stronger consensus rating and higher probable upside, analysts plainly believe Medline is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Medline beats Koninklijke Philips on 9 of the 13 factors compared between the two stocks.

How does Koninklijke Philips compare to GE HealthCare Technologies?

Koninklijke Philips (NYSE:PHG) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Koninklijke Philips has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

GE HealthCare Technologies has a consensus target price of $80.21, indicating a potential upside of 24.26%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, analysts plainly believe GE HealthCare Technologies is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
GE HealthCare Technologies	0 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50

Koninklijke Philips pays an annual dividend of $0.86 per share and has a dividend yield of 3.3%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Koninklijke Philips pays out 73.5% of its earnings in the form of a dividend. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GE HealthCare Technologies has raised its dividend for 1 consecutive years.

GE HealthCare Technologies has a net margin of 9.10% compared to Koninklijke Philips' net margin of 5.49%. GE HealthCare Technologies' return on equity of 20.46% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
GE HealthCare Technologies	9.10%	20.46%	5.73%

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 0.4% of GE HealthCare Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, GE HealthCare Technologies had 12 more articles in the media than Koninklijke Philips. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 3 mentions for Koninklijke Philips. GE HealthCare Technologies' average media sentiment score of 1.01 beat Koninklijke Philips' score of 0.40 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GE HealthCare Technologies	8 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has higher revenue and earnings than Koninklijke Philips. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.24	$1.01B	$1.17	22.12
GE HealthCare Technologies	$20.63B	1.42	$2.08B	$4.18	15.44

Summary

GE HealthCare Technologies beats Koninklijke Philips on 16 of the 18 factors compared between the two stocks.

How does Koninklijke Philips compare to Zimmer Biomet?

Koninklijke Philips (NYSE:PHG) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, Zimmer Biomet had 15 more articles in the media than Koninklijke Philips. MarketBeat recorded 18 mentions for Zimmer Biomet and 3 mentions for Koninklijke Philips. Zimmer Biomet's average media sentiment score of 0.93 beat Koninklijke Philips' score of 0.40 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zimmer Biomet	12 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Koninklijke Philips has higher revenue and earnings than Zimmer Biomet. Koninklijke Philips is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.24	$1.01B	$1.17	22.12
Zimmer Biomet	$8.23B	2.04	$705.20M	$3.85	22.56

13.7% of Koninklijke Philips shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Koninklijke Philips pays an annual dividend of $0.86 per share and has a dividend yield of 3.3%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.1%. Koninklijke Philips pays out 73.5% of its earnings in the form of a dividend. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Zimmer Biomet has a consensus price target of $102.70, indicating a potential upside of 18.24%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Zimmer Biomet has a net margin of 9.05% compared to Koninklijke Philips' net margin of 5.49%. Koninklijke Philips' return on equity of 13.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	5.49%	13.51%	5.48%
Zimmer Biomet	9.05%	13.24%	7.28%

Summary

Zimmer Biomet beats Koninklijke Philips on 14 of the 19 factors compared between the two stocks.

How does Koninklijke Philips compare to Solventum?

Solventum (NYSE:SOLV) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Solventum presently has a consensus target price of $84.25, suggesting a potential upside of 2.61%. Given Solventum's stronger consensus rating and higher probable upside, research analysts clearly believe Solventum is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Solventum has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

In the previous week, Solventum and Solventum both had 3 articles in the media. Koninklijke Philips' average media sentiment score of 0.40 beat Solventum's score of 0.25 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solventum has higher earnings, but lower revenue than Koninklijke Philips. Solventum is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.71	$1.56B	$8.16	10.06
Koninklijke Philips	$20.17B	1.24	$1.01B	$1.17	22.12

13.7% of Koninklijke Philips shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Solventum has a net margin of 17.33% compared to Koninklijke Philips' net margin of 5.49%. Solventum's return on equity of 23.51% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Koninklijke Philips	5.49%	13.51%	5.48%

Summary

Solventum beats Koninklijke Philips on 10 of the 15 factors compared between the two stocks.

How does Koninklijke Philips compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Koninklijke Philips has higher revenue and earnings than Smith & Nephew SNATS.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.10	$625M	N/A	N/A
Koninklijke Philips	$20.17B	1.24	$1.01B	$1.17	22.12

Smith & Nephew SNATS presently has a consensus price target of $30.93, suggesting a potential upside of 1.78%. Given Smith & Nephew SNATS's stronger consensus rating and higher probable upside, research analysts plainly believe Smith & Nephew SNATS is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are owned by institutional investors. 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Koninklijke Philips has a net margin of 5.49% compared to Smith & Nephew SNATS's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Koninklijke Philips	5.49%	13.51%	5.48%

Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. Koninklijke Philips pays an annual dividend of $0.86 per share and has a dividend yield of 3.3%. Koninklijke Philips pays out 73.5% of its earnings in the form of a dividend.

In the previous week, Koninklijke Philips had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 3 mentions for Koninklijke Philips and 2 mentions for Smith & Nephew SNATS. Koninklijke Philips' average media sentiment score of 0.40 beat Smith & Nephew SNATS's score of 0.00 indicating that Koninklijke Philips is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Smith & Nephew SNATS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Summary

Koninklijke Philips beats Smith & Nephew SNATS on 9 of the 16 factors compared between the two stocks.

Get Koninklijke Philips News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHG vs. The Competition

Export

Metric	Koninklijke Philips	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$24.89B	$8.24B	$6.44B	$23.28B
Dividend Yield	3.39%	2.61%	2.69%	4.06%
P/E Ratio	22.15	15.50	23.92	31.04
Price / Sales	1.24	7.13	525.35	24.10
Price / Cash	8.23	17.10	41.34	24.93
Price / Book	2.00	3.61	9.98	4.71
Net Income	$1.01B	$224.05M	$3.56B	$1.07B
7 Day Performance	-2.20%	-0.74%	-0.71%	-0.26%
1 Month Performance	N/A	N/A	N/A	2.47%
1 Year Performance	12.59%	2.50%	29.11%	25.87%

Koninklijke Philips Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHG Koninklijke Philips	3.0636 of 5 stars	$25.88 +2.1%	N/A	+11.1%	$24.89B	$20.17B	22.15	65,340
MDLN Medline	3.7642 of 5 stars	$35.75 -2.2%	$50.65 +41.7%	N/A	$48.03B	$28.43B	N/A	43,000	Analyst Forecast
GEHC GE HealthCare Technologies	4.9318 of 5 stars	$62.69 +0.6%	$80.21 +27.9%	-12.8%	$28.36B	$20.63B	15.00	54,000	Positive News
ZBH Zimmer Biomet	4.4447 of 5 stars	$82.83 +0.6%	$102.70 +24.0%	-7.4%	$15.93B	$8.41B	21.51	17,000	Positive News Insider Trade
SOLV Solventum	2.5357 of 5 stars	$75.97 +1.4%	$84.25 +10.9%	+5.6%	$12.98B	$8.26B	9.31	20,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PHG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Koninklijke Philips (PHG) Competitors

PHG vs. MDLN, GEHC, ZBH, SOLV, and SNN

How does Koninklijke Philips compare to Medline?

Summary

How does Koninklijke Philips compare to GE HealthCare Technologies?

Summary

How does Koninklijke Philips compare to Zimmer Biomet?

Summary

How does Koninklijke Philips compare to Solventum?

Summary

How does Koninklijke Philips compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHG vs. The Competition

Koninklijke Philips Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Koninklijke Philips (PHG) Competitors

PHG vs. MDLN, GEHC, ZBH, SOLV, and SNN

How does Koninklijke Philips compare to Medline?

Which has stronger valuation & earnings, MDLN or PHG?

Does the media refer more to MDLN or PHG?

Do institutionals & insiders believe in MDLN or PHG?

Is MDLN or PHG more profitable?

Do analysts recommend MDLN or PHG?

Summary

How does Koninklijke Philips compare to GE HealthCare Technologies?

Which has more risk & volatility, PHG or GEHC?

Do analysts rate PHG or GEHC?

Is PHG or GEHC a better dividend stock?

Is PHG or GEHC more profitable?

Do insiders and institutionals have more ownership in PHG or GEHC?

Does the media favor PHG or GEHC?

Which has better earnings & valuation, PHG or GEHC?

Summary

How does Koninklijke Philips compare to Zimmer Biomet?

Does the media prefer PHG or ZBH?

Which has more volatility & risk, PHG or ZBH?

Which has higher valuation & earnings, PHG or ZBH?

Do insiders and institutionals believe in PHG or ZBH?

Is PHG or ZBH a better dividend stock?

Do analysts recommend PHG or ZBH?

Is PHG or ZBH more profitable?

Summary

How does Koninklijke Philips compare to Solventum?

Do analysts recommend SOLV or PHG?

Which has more volatility and risk, SOLV or PHG?

Does the media favor SOLV or PHG?

Which has higher valuation & earnings, SOLV or PHG?

Do insiders & institutionals have more ownership in SOLV or PHG?

Is SOLV or PHG more profitable?

Summary

How does Koninklijke Philips compare to Smith & Nephew SNATS?

Which has preferable earnings and valuation, SNN or PHG?

Do analysts rate SNN or PHG?

Do insiders & institutionals believe in SNN or PHG?

Is SNN or PHG more profitable?

Is SNN or PHG a better dividend stock?

Does the media prefer SNN or PHG?

Which has more risk & volatility, SNN or PHG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHG vs. The Competition

Koninklijke Philips Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools